Recombinant Human TNF-α protein (His Tag) (PDMH100384)
 
                        For research use only.
| Synonyms | Cachectin, TNF, TNF-Alpha, TNF-a, TNFA, TNFSF2, Tumor Necrosis Factor, Tumor Necrosis Factor Ligand Superfamily Member 2 | 
| Species | Human | 
| Expression Host | HEK293 Cells | 
| Sequence | Val77-Leu233 | 
| Accession | P01375 | 
| Calculated Molecular Weight | 17.2 kDa | 
| Observed Molecular Weight | 15 kDa | 
| Tag | C-His | 
| Bio-activity | Not validated for activity | 
| Form | Lyophilized powder | 
| Purity | > 95% as determined by reducing SDS-PAGE. | 
| Endotoxin | < 1.0 EU/mg of the protein as determined by the LAL method | 
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. | 
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. | 
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. | 
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. | 
| Background | Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo. | 
Other Clones
{{antibodyDetailsPage.numTotal}} Results
- 
                                    
                                    
                                    {{item.title}}
                                    Citations ({{item.publications_count}}) Manual MSDS Cat.No.:{{item.cat}} {{index}} {{goods_show_value}} 
Other Formats
{{formatDetailsPage.numTotal}} Results
- 
                                    
                                    
                                    {{item.title}}
                                    Citations ({{item.publications_count}}) Manual MSDS Cat.No.:{{item.cat}} {{index}} {{goods_show_value}} 
- 
                                    
                                    IF:{{item.impact}} Journal:{{item.journal}} ({{item.year}}) DOI:{{item.doi}}Reactivity:{{item.species}} Sample Type:{{item.organization}} 
- 
                                    Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}} 
 
                            

 
                